# Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia

> **NCT01522976** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 282 (actual)

## Conditions studied

- Chronic Myelomonocytic Leukemia
- Chronic Myelomonocytic Leukemia-1
- Chronic Myelomonocytic Leukemia-2
- Myelodysplastic Syndrome
- Myelodysplastic Syndrome With Excess Blasts
- Myelodysplastic Syndrome With Excess Blasts-1
- Myelodysplastic Syndrome/Acute Myeloid Leukemia

## Interventions

- **DRUG:** Azacitidine
- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Lenalidomide
- **DRUG:** Vorinostat

## Key facts

- **NCT ID:** NCT01522976
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2012-03-01
- **Primary completion:** 2015-06-01
- **Final completion:** 2027-03-31
- **Target enrollment:** 282 (ACTUAL)
- **Last updated:** 2026-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01522976

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01522976, "Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01522976. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*